Targeted cancer therapeutics: Biosynthetic and energetic pathways characterized by metabolomics and the interplay with key cancer regulatory factors

Current Pharmaceutical Design

Volumn 20, Issue 15, 2014, Pages 2637-2647

  Dang, Ngoc Ha T ^a   Singla, Arvind K ^a   Mackay, Emily M ^a   Jirik, Frank R ^a   Weljie, Aalim M ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cancer; Energy reprogramming; Hypoxia; Metabolomics; Targeted therapy development

Indexed keywords

AMINO ACID DERIVATIVE; FATTY ACID; MAMMALIAN TARGET OF RAPAMYCIN; MYC PROTEIN; NUCLEOTIDE; PROTEIN P53; HYPOXIA INDUCIBLE FACTOR 1; PHOSPHATIDYLINOSITOL 3 KINASE;

ARTICLE; BIOENERGY; CANCER CELL; CANCER SURVIVAL; CANCER THERAPY; CELL METABOLISM; CELL SURVIVAL; FATTY ACID METABOLISM; GLYCOLYSIS; HUMAN; HYPOXIA; LIPID METABOLISM; LUNG CANCER; LUNG CANCER CELL LINE; METABOLOMICS; METASTASIS; NUCLEOTIDE METABOLISM; PRIORITY JOURNAL; REGULATORY MECHANISM; WESTERN BLOTTING; BIOSYNTHESIS; CELL HYPOXIA; ENERGY METABOLISM; METABOLISM; MITOCHONDRION; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PHYSIOLOGY;

CELL HYPOXIA; ENERGY METABOLISM; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; METABOLOMICS; MITOCHONDRIA; MOLECULAR TARGETED THERAPY; NEOPLASMS; NUCLEOTIDES; PHOSPHATIDYLINOSITOL 3-KINASES;

EID: 84903698645     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990489     Document Type: Article

References (119)

1. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol 1959; 37: 911-7.
2. Hiller K, Hangebrauk J, Jäger C, Spura J, Schreiber K, Schomburg D. MetaboliteDetector: comprehensive analysis tool for targeted and nontargeted GC/MS based metabolome analysis. Anal Chem 2009; 81: 3429-39.
3. Kopka J, Schauer N, Krueger S, Birkemeyer C, Usadel B, Bergmüller E, et al. GMD@CSB. DB: the Golm Metabolome Database. Bioinformatics 2005; 21(8): 1635-8.
4. Wolf A, Agnihotri S, Guha A. Targeting metabolic remodeling in glioblastoma multiforme. Oncotarget 2010; 1(7): 552-62.
5. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation. Science 2009; 324(5930): 1029-33.
6. Warburg O. On the Origin of Cancer Cells. Science1956; 123: 309-14.
7. Anand P, Kunnumakkara AB, Kunnumakara AB, et al. Cancer is a preventable disease that requires major lifestyle changes. Pharm Res 2008; 25(9): 2097-116.
8. Irigaray P, Newby JA, Clapp R, et al. Lifestyle-related factors and environmental agents causing cancer: an overview. Biome pharmacother 2007; 61(10): 640-58.
9. Griffin JL, Shockcor JP. Metabolic profiles of cancer cells. Nat Rev Cancer 2004; 4(7): 551-61.
10. Mamas M, Dunn WB, Neyses L, Goodacre R. The role of metabolites and metabolomics in clinically applicable biomarkers of disease. Arch Toxicol 2011; 85(1): 5-17.
11. Dunn WB, Broadhurst DI, Atherton HJ, Goodacre R, Griffin JL. Systems level studies of mammalian metabolomes: the roles of mass spectrometry and nuclear magnetic resonance spectroscopy. Chem Soc Rev 2011; 40(1): 387-426.
12. Zhang A, Sun H, Wang X. Serum metabolomics as a novel diagnostic approach for disease: a systematic review. Anal Bioanal Chem 2012; 404(4): 1239-45.
13. Weljie AM, Bondareva A, Zang P, Jirik FR. (1)H NMR metabolomics identification of markers of hypoxia-induced metabolic shifts in a breast cancer model system. J Biomol NMR 2011; 49(3-4): 185-93.
14. Bathe OF, Shaykhutdinov R, Kopciuk K, et al. Feasibility of identifying pancreatic cancer based on serum metabolomics. Cancer Epidemiology Biomarkers Prev 2011; 20(1): 140-7.
15. Farshidfar F, Weljie AM, Kopciuk K, et al. Serum metabolomic profile as a means to distinguish stage of colorectal cancer. Genome Med 2012; 4(5): 42.
16. Fan TW-M, Lane AN. NMR-based stable isotope resolved metabolomics in systems biochemistry. J Biomol NMR 2011; 49(3-4): 267-80.
17. Dunn WB, Bailey NJC, Johnson HE. Measuring the metabolome: current analytical technologies. Analyst 2005; 130(5): 606-25.
18. Seyfried TN, Shelton LM. Cancer as a metabolic disease. Nutr Metab 2010; 7(7): 1-22.
19. Muñoz-Pinedo C, El Mjiyad N, Ricci J-E. Cancer metabolism: current perspectives and future directions. Cell death Dis 2012; 3(1): e248.
20. Chen Z, Zhang H, Lu W, Huang P. Role of mitochondriaassociated hexokinase II in cancer cell death induced by 3-bromopyruvate. Bichim Biophys Acta 2009; 63(21): 7330-7.
21. Zhou W, Simpson PJ, Mcfadden JM, et al. Fatty Acid Synthase Inhibition Triggers Apoptosis during S Phase in Human Cancer Cells Fatty Acid Synthase Inhibition Triggers Apoptosis during S Phase in Human. Cancer Res 2003; 63(21): 7330-7.
22. Chiaradonna F, Moresco RM, Airoldi C, et al. From cancer metabolism to new biomarkers and drug targets. Biotechnol Adv 2012; 30(1): 30-51.
23. Tennant DA, Durán R V, Gottlieb E. Targeting metabolic transformation for cancer therapy. Nat Rev Cancer 2010; 10(4): 267-77.
24. Weljie AM, Jirik FR. Hypoxia-induced metabolic shifts in cancer cells: Moving beyond the Warburg effect. Int J Biochem Cell Biol 2011; 43(7): 981-9.
25. Dunn WB, Broadhurst D, Begley P, et al. Procedures for largescale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat Proc 2011; 6(7): 1060-83.
26. De Graaf R a, Behar KL. Quantitative 1H NMR spectroscopy of blood plasma metabolites. Anal Chem 2003; 75(9): 2100-4.
27. Weljie AM, Newton J, Mercier P, Carlson E, Slupsky CM. Targeted profiling: quantitative analysis of 1H NMR metabolomics data. Anal Chem 2006; 78(13): 4430-42.
28. Zhang S, Nagana Gowda GA, Ye T, Raftery D. Advances in NMRbased biofluid analysis and metabolite profiling. Analyst 2010; 135(7): 1490-8.
29. Spratlin JL, Serkova NJ, Eckhardt SG. Clinical applications of metabolomics in oncology: a review. Clinical cancer research: an official J Am Assoc Cancer Res 2009; 15(2): 431-40.
30. Cuperlovic-Culf M, Barnett D a, Culf AS, Chute I. Cell culture metabolomics: applications and future directions. Drug Discov Today 2010; 15(15-16): 610-21.
31. Metallo CM, Walther JL, Stephanopoulos G. Evaluation of 13C isotopic tracers for metabolic flux analysis in mammalian cells. J Biotechnol 2009; 144(3): 167-74.
32. Yang C, Richardson AD, Osterman A, Smith JW. Profiling of central metabolism in human cancer cells by two-dimensional NMR, GC-MS analysis, and isotopomer modeling. Metabolomics 2008; 4: 13-29.
33. Fan TWM, Lane AN, Higashi RM, et al. Altered regulation of metabolic pathways in human lung cancer discerned by (13)C stable isotope-resolved metabolomics (SIRM). Mol Cancer 2009; 8: 41.
34. Ye T, Mo H, Shanaiah N, Gowda G a N, Zhang S, Raftery D. Chemoselective 15N tag for sensitive and high-resolution nuclear magnetic resonance profiling of the carboxyl-containing metabolome. Anal Chem 2009; 81(12): 4882-8.
35. Gowda G a N, Tayyari F, Ye T, et al. Quantitative Analysis of Blood Plasma Metabolites Using Isotope Enhanced NMR Methods. Anal Chem 2010; 82(21): 8983-90.
36. DeSilva MA, Shanaiah N, Nagana Gowda GA, Rosa-Pérez K, Hanson BA, Raftery D. Application of 31P NMR spectroscopy and chemical derivatization for metabolite profiling of lipophilic compounds in human serum. Magn Reson Chem 2009; 47 Suppl 1(June): S74-80.
37. Boros LG, Cascante M, Lee WNP. Metabolic profiling of cell growth and death in cancer: applications in drug discovery. Drug Discov Today 2002; 7(6): 364-72.
38. Paul Lee W-N, Wahjudi PN, Xu J, Go VL. Tracer-based metabolomics: concepts and practices. Clin Biochem 2010; 43(16-17): 1269-77.
39. Boros G, Lerner MR, Ascp HT, et al. [1,2-13C2]-D-Glucose profile of the serum, liver, pancreas and DMBA-induced pancreatic tumors of rats. Pancreas 2005; 31(4): 337-43.
40. Owen OE, Kalhan SC, Hanson RW. The key role of anaplerosis and cataplerosis for citric acid cycle function. J Biol Chem 2002; 277(34): 30409-12.
41. Lane AN, Fan TW-M, Higashi RM. Stable isotope-assisted metabolomics in cancer research. IUBMB life 2008; 60(2): 124-9.
42. Eriksson I, Johansson E, Kettaneneh-Wold N, Wold S. Multi-and Megavariate Data Analysis, Priciples and Application. Umetrics Academy: Umea 2001.
43. Westerhuis JA, Van Velzen EJJ, Hoefsloot HCJ, Smilde AK. Multivariate paired data analysis: multilevel PLSDA versus OPLSDA. Metabolomics 2010; 6(1): 119-28.
44. Ebbels TMD, Cavill R. Bioinformatic methods in NMR-based metabolic profiling. Progress in Nuclear Magnetic Resonance Spectroscopy. Prog Nucl Mag Res Sp 2009; 55(4): 361-74.
45. Booth SC, Weljie AM, Turner RJ. Computational Tools for the Secondary Analysis of Metabolomics Experiments. Comput Structural Biotechnol J 2013; 4(5): e201301003.
46. Xia J, Mandal R, Sinelnikov I V, Broadhurst D, Wishart DS. MetaboAnalyst 2.0: a comprehensive server for metabolomic data analysis. Nucleic Acids Res 2012; 40: W127-33.
47. Hanahan D, Weinberg R a. Hallmarks of cancer: the next generation. Cell 2011; 144(5): 646-74.
48. Giatromanolaki a, Koukourakis MI, Sivridis E, et al. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumors and survival. Br J Cancer 2001; 85(6): 881-90.
49. Keith B, Johnson RS, Simon MC. HIF1α and HIF2α: sibling rivalry in hypoxic tumor growth and progression. Nat Rev Cancer. Nature Publishing Group; 2012; 12: 9-22.
50. Rankin EB, Giaccia a J. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 2008; 15(4): 678-85.
51. Bao B, Azmi AS, Ali S, et al. The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness. Bichim Biophys Acta 2012; 1826(2): 272-96.
52. Düvel K, Yecies JL, Menon S, et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell 2010; 39(2): 171-83.
53. Shim H, Dolde C, Lewis BC, et al. C-Myc transactivation of LDHA: Implications for tumor metabolism and growth. Proc Natl Acad Sci USA1997; 94(13): 6658-63.
54. Dang CV, Le A, Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res 2009; 15(21): 6479-83.
55. Loboda A, Jozkowicz A, Dulak J. HIF-1 and HIF-2 transcription factors--similar but not identical. Mol Cells 2010; 29(5): 435-42.
56. Mazumdar J, Hickey MM, Pant DK, Durham AC, Sweet-cordero A. HIF-2α deletion promotes Kras-driven lung tumor development. Proc Natl Acad Sci USA 2010; 107(32): 14282-7.
57. Kim J, Tchernyshyov I, Semenza GL, Dang C V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006; 3(3): 177-85.
58. Hu C, Wang L, Chodosh LA, Keith B, Simon MC. Differential Roles of Hypoxia-Inducible Factor 1 α (HIF-1α) and HIF-2α in Hypoxic Gene Regulation. Mol Cell Biol 2003; 23(24): 9361-74.
59. Christofk HR, Vander Heiden MG, Harris MH, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumor growth. Nature 2008; 452(7184): 230-3.
60. Clem B, Telang S, Clem A, et al. Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth. Mol Cancer Ther 2008; 7(1): 110-20.
61. Le A, Cooper CR, Gouw AM, et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci USA 2010; 107(5): 2037-42.
62. Pistollato F, Abbadi S, Rampazzo E, et al. Hypoxia and succinate antagonize 2-deoxyglucose effects on glioblastoma. Biochem Pharmacol 2010; 80(10): 1517-27.
63. Ihrlund LS, Hernlund E, Khan O, Shoshan MC. 3-Bromopyruvate as inhibitor of tumor cell energy metabolism and chemopotentiator of platinum drugs. Mol Oncol 2008; 2(1): 94-101.
64. Ko YH, Pedersen PL, Geschwind JF. Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. Cancer Lett 2001; 173(1): 83-91.
65. Seyfried TN, Kiebish MA, Mukherjee P. Targeting Energy Metabolism in Brain Cancer with Restricted Diets. Springer New York 2010; pp. 341-63.
66. Vander Heiden MG. Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug discovery 2011; 10: 671-84.
67. Cheong J-H, Park ES, Liang J, et al. Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models. Mol Cancer Ther 2011; 10(12): 2350-62.
68. Semenza GL. HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev 2011; 20(1): 1-10.
69. Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell 2011; 147(2): 275-92.
70. Spano D, Heck C, Antonellis P De, Christofori G, Zollo M. Molecular networks that regulate cancer metastasis. Semin Cancer Biol 2012; 22: 234-49.
71. Jemal A, Bray F, Ferlay J. Global Cancer Statistics. CA Cancer J Clin 2011; 61(2): 69-90.
72. Lu X, Kang Y. Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res 2010; 16(24): 5928-35.
73. Mucaj V, Shay JES, Simon MC. Effects of hypoxia and HIFs on cancer metabolism. Int J of Hematol 2012; 95(5): 464-70.
74. Bos PD, Zhang XH-F, Nadal C, et al. Genes that mediate breast cancer metastasis to the brain. Nature 2009; 459(7249): 1005-9.
75. Rana S, Singla AK, Bajaj A, et al. Array-based sensing of metastatic cells and tissues using nanoparticle-fluorescent protein conjugates. ACS nano 2012; 6(9): 8233-40.
76. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959; 37: 911-7.
77. Li Z, Bao S, Wu Q, et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 2009; 15(6): 501-13.
78. Liu MY, Poellinger L, Walker CL, Tumor T, Gene S. Up-Regulation of Hypoxia-inducible Factor 2 α in Renal Cell Carcinoma Associated with Loss of Tsc-2 Tumor Suppressor Gene. Cancer Res 2003; 63(10): 2675-80.
79. Tong X, Zhao F, Thompson CB. The molecular determinants of de novo nucleotide biosynthesis in cancer cells. Curr Opin Genet Dev 2009; 19(1): 32-7.
80. Liu Y-C, Li F, Handler J, et al. Global regulation of nucleotide biosynthetic genes by c-Myc. PloS one 2008; 3(7): e2722.
81. Wise DR, DeBerardinis RJ, Mancuso A, et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci USA 2008; 105(48): 18782-7.
82. DeBerardinis RJ, Mancuso A, Daikhin E, et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA 2007; 104(49): 19345-50.
83. Deberardinis RJ, Sayed N, Ditsworth D, Thompson CB. Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev 2008; 18(1): 54-61.
84. Bensaad K, Tsuruta A, Selak MA, et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006; 126(1): 107-20.
85. Maddocks ODK, Vousden KH. Metabolic regulation by p53. J Mol Med (Berl) 2011; 89(3): 237-45.
86. Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: Mechanisms of Action and Clinical Strategies. Nat Rev. Cancer 2003; 3(5): 330-8.
87. Gade TPF, Spees WM, Le HC, et al. In vivo 5-fluorouracil and fluoronucleotide T1 relaxation time measurements using the variable nutation angle method. Magn Reson Med 2004; 52(1): 169-73.
88. Kuhajda FP. Fatty acid synthase and cancer: new application of an old pathway. Cancer Res 2006; 66(12): 5977-80.
89. Wang C, Xu C, Sun M, Luo D, Liao DF, Cao D. Acetyl-CoA carboxylase-alpha inhibitor TOFA induces human cancer cell apoptosis. Biochem Biophys Res Commun 2009; 385(3): 302-6.
90. Tong L, Harwood HJ. Acetyl-coenzyme A carboxylases: versatile targets for drug discovery. J Cell Biochem 2006; 99(6): 1476-88.
91. Kuhajda FP. Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition 2000; 16(3): 202-8.
92. Migita T, Narita T, Nomura K, et al. ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer. Cancer Res 2008; 68: 8547-54.
93. Mashima T, Seimiya H, Tsuruo T. De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy. Br J Cancer 2009; 100(9): 1369-72.
94. Kuhajda FP, Pizer ES, Li JN, Mani NS, Frehywot GL, Townsend CA. Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc Nat Acad Sci USA 2000; 97(7): 3450-4.
95. Johnston ALM, Lun X, Rahn JJ, et al. The p75 neurotrophin receptor is a central regulator of glioma invasion. PLoS biology 2007; 5(8): e212.
96. Laplante M, Sabatini DM. An emerging role of mTOR in lipid biosynthesis. Curr Biol 2009; 19(22): R1046-52.
97. Deberardinis RJ, Lum JJ, Thompson CB. Phosphatidylinositol 3-kinase-dependent modulation of carnitine palmitoyltransferase 1A expression regulates lipid metabolism during hematopoietic cell growth. J Biol Chem 2006; 281(49): 37372-80.
98. Fresno Vara JA, Casado E, De Castro J, Cejas P, Belda-Iniesta C, González-Barón M. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 2004; 30(2): 193-204.
99. Puzio-Kuter AM. The Role of p53 in Metabolic Regulation. Genes Cancer 2011; 2(4): 385-91.
100. Erchia AMD, Tullo A, Lefkimmiatis K, Saccone C, Sbisà E. The Fatty Acid Synthase Gene is a Conserved p53 Family Target from Worm to Human. Cell Cycle 2006; 5(7): 750-8.
101. Ralph SJ, Rodríguez-Enríquez S, Neuzil J, Moreno-Sánchez R. Bioenergetic pathways in tumor mitochondria as targets for cancer therapy and the importance of the ROS-induced apoptotic trigger. Mol Aspects Med 2010; 31(1): 29-59.
102. Wallace DC. Mitochondria and cancer. Nat Rev Cancer 2012; 12(10): 685-98.
103. Pópulo H, Lopes JM, Soares P. The mTOR Signalling Pathway in Human Cancer. Int J Mol Sci 2012; 13(2): 1886-918.
104. Liu W, Le A, Hancock C, et al. Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC. Proc Natl Acad Sci USA 2012; 109(23): 8983-8.
105. Jordan BF, Black K, Robey IF, Runquist M, Powis G, Gillies RJ. Metabolite changes in HT-29 xenograft tumors following HIF-1alpha inhibition with PX-478 as studied by MR spectroscopy in vivo and ex vivo. NMR Biomed 2005; 18(7): 430-9.
106. Schwartz DL, Powis G, Thitai-Kumar A, et al. The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects. Mol Cancer Ther 2009; 8(4): 947-58.
107. Lee K, Zhang H, Qian DZ, Rey S, Liu JO, Semenza GL. Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. Proc Natl Acad Sci USA 2009; 106(42): 17910-5.
108. Hermeking H. The MYC oncogene as a cancer drug target. Curr Cancer Drug Targets 2003; 3(3): 163-75.
109. Albihn A, Johnsen JI, Henriksson MA. MYC in oncogenesis and as a target for cancer therapies. Adv Cancer Res 2010; 107(10): 163-224.
110. Guo J, Parise RA, Joseph E, et al. Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z, E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice. Cancer chemother Pharmacol 2009; 63(4): 615-25.
111. Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M, et al. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 2002; 297(5578): 102-4.
112. Giuriato S, Ryeom S, Fan AC, et al. Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch. Proc Natl Acad Sci USA 2006; 103(44): 16266-71.
113. Lane DP, Cheok CF, Lain S. P53-Based Cancer Therapy. Cold Spring Harb Perspect Biol 2010; 2(9): a001222.
114. Suzuki K, Matsubara H. Recent advances in p53 research and cancer treatment. J Biomed Biotech 2011; 2011: 978312.
115. Chène P. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat Rev. Cancer 2003; 3(2): 102-9.
116. Colombo N, McMeekin DS, Schwartz PE, et al. Ridaforolimus as a single agent in advanced endometrial cancer: results of a singlearm, phase 2 trial. Br J Cancer 2013; 108(5): 1021-6.
117. Engelman JA, Chen L, Tan X, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008; 14(12): 1351-6.
118. Liu T-J, Koul D, LaFortune T, et al. NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol Cancer Ther 2009; 8(8): 2204-10.
119. Serra V, Markman B, Scaltriti M, et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 2008; 68(19): 8022-30.